Nothing is Better Than Guardant Health Inc. (GH) stock at the moment

Guardant Health Inc. (NASDAQ: GH) stock jumped 10.69% on Wednesday to $54.89 against a previous-day closing price of $49.59. With 0.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.91 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $55.15 whereas the lowest price it dropped to was $50.28. The 52-week range on GH shows that it touched its highest point at $126.36 and its lowest point at $27.65 during that stretch. It currently has a 1-year price target of $94.08. Beta for the stock currently stands at 0.78.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GH was up-trending over the past week, with a rise of 2.18%, but this was up by 9.45% over a month. Three-month performance surged to 30.57% while six-month performance fell -18.68%. The stock lost -55.19% in the past year, while it has lost -45.12% so far this year. A look at the trailing 12-month EPS for GH yields -5.41 with Next year EPS estimates of -5.14. For the next quarter, that number is -1.36. This implies an EPS growth rate of -53.80% for this year and 15.70% for next year. EPS is expected to grow by 12.60% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -48.60%.

Float and Shares Shorts:

At present, 102.05 million GH shares are outstanding with a float of 97.42 million shares on hand for trading. On Jul 14, 2022, short shares totaled 3.91 million, which was 3.83% higher than short shares on Jun 14, 2022. In addition to Dr. Helmy Eltoukhy Ph.D. as the firm’s Co-Founder, Co-CEO & Chairman, Dr. AmirAli Talasaz Ph.D. serves as its Co-CEO & Director.


Institutional Ownership:

Through their ownership of 92.83% of GH’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 58.84% of GH, in contrast to 35.39% held by mutual funds. Shares owned by individuals account for 31.34%. As the largest shareholder in GH with 12.25% of the stake, Fidelity Management & Research Co holds 12,517,688 shares worth 12,517,688. A second-largest stockholder of GH, The Vanguard Group, Inc., holds 8,706,649 shares, controlling over 8.52% of the firm’s shares. Capital Research & Management Co is the third largest shareholder in GH, holding 5,577,865 shares or 5.46% stake. With a 2.88% stake in GH, the American Funds Growth Fund of Ame is the largest stakeholder. A total of 2,943,323 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.81% of GH stock, is the second-largest Mutual Fund holder. It holds 2,875,389 shares valued at 143.94 million. Vanguard Small Cap Index Fund holds 2.40% of the stake in GH, owning 2,455,383 shares worth 122.92 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GH since 17 analysts follow the stock currently. There are 14 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GH analysts setting a high price target of $130.00 and a low target of $65.00, the average target price over the next 12 months is $96.46. Based on these targets, GH could surge 136.84% to reach the target high and rise by 18.42% to reach the target low. Reaching the average price target will result in a growth of 75.73% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. GH will report FY 2022 earnings on 02/22/2023. Analysts have provided yearly estimates in a range of -$5.62 being high and -$8.22 being low. For GH, this leads to a yearly average estimate of -$6.27. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Guardant Health Inc. surprised analysts by -$1.04 when it reported -$2.25 EPS against a consensus estimate of -$1.21. The surprise factor in the prior quarter was $0.00. Based on analyst estimates, the high estimate for the next quarter is -$1.04 and the low estimate is -$2.30. The average estimate for the next quarter is thus -$1.39.

Summary of Insider Activity:

Insiders traded GH stock several times over the past three months with 3 Buys and 3 Sells. In these transactions, 5,862 shares were bought while 11,000 shares were sold. The number of buy transactions has increased to 32 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 262,107 while 44,640 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *

1406

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam